Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases

Current Opinion in Investigational Drugs

Volumn 9, Issue 2, 2008, Pages 184-188

  Dadachova, E ^a   Casadevall, A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Immunotoxin; Monoclonal antibodies; Radioimmunotherapy; Safety; Viral cancers

Indexed keywords

DOXORUBICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18B7; MONOCLONAL ANTIBODY 18B7 BI 213; MONOCLONAL ANTIBODY D11; MONOCLONAL ANTIBODY D11 BI 213; MONOCLONAL ANTIBODY GP41; MONOCLONAL ANTIBODY P4D10; UNCLASSIFIED DRUG;

BACTERIAL CELL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCUS NEOFORMANS; FUNGAL CELL; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MYCOSIS; NONHUMAN; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; RADIOIMMUNOTHERAPY;

EID: 38849103765     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Kim SJ, Park Y, Hong HJ: Antibody engineering for the development of therapeutic antibodies. Mol Cells (2005) 20(1):17-29.
2. Casadevall A, Dadachova E, Pirofski LA: Passive antibody therapy for infectious diseases. Nat Rev Microbiol (2004) 2(9):695-703. •• This paper presents a historical perspective and summarizes the current state of passive antibody therapy of infectious diseases.
3. McCarron PA, Olwill SA, Marouf WM, Buick RJ, Walker B, Scott CJ: Antibody conjugates and therapeutic strategies. Mol Interv (2005) 5(6):368-380. •• A detailed overview of current techniques to arm antibodies with various cytotoxic payloads.
4. Till MA, Zolla-Pazner S, Gorny MK, Patton JS, Uhr JW, Vitetta ES: Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci USA (1989) 86(6):1987-1991.
5. Till MA, Ghetie V, May RD, Auerbach PC, Zolla-Pazner S, Gorny MK, Gregory T, Uhr JW, Vitetta ES: Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. J Acquir Immune Defic Syndr (1990) 3(6):609-614.
6. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC: Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J Infect Dis (1994) 170(4):1009-1013.
7. Davey RT Jr, Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, Cox SR, Polis MA, Kovacs JA, Falloon J: Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis (1994) 170(5):1180-1188.
8. Vitetta ES: Immunotoxins: New therapeutic reagents for autoimmunity, cancer, and AIDS. J Clin Immunol (1990) 10(6 Suppl):15S-18S. •• This review summarizes the reasons for failure of immunotoxins as anti-HIV agents in the 1980s.
9. Saavedra-Lozano J, McCoig C, Xu J, Cao Y, Keiser P, Ghetie V, Siliciano RF, Siliciano JD, Picker LJ, Ramilo O, Vitetta ES: An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons. J Infect Dis (2002) 185(3):306-314.
10. Saavedra-Lozano J, Cao Y, Callison J, Sarode R, Sodora D, Edgar J, Hatfield J, Picker L, Peterson D, Ramilo O, Vitetta ES: An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory. Proc Natl Acad Sci USA (2004) 101(8):2494-2499. • A study describes the targeting of certain subsets of CD45RO cells with a ricin A chain-armed antibody.
11. Pincus SH, Fang H, Wilkinson RA, Marcotte TK, Robinson JE, Olson WC: In vivo efficacy of anti-glycoprotein 41, but not antiglycoprotein 120, immunotoxins in a mouse model of HIV infection. J Immunol (2003) 170(4):2236-2241. • A study targeting viral envelope proteins on HIV-infected cells with antibodies armed with ricin A chain.
12. Johansson S, Goldenberg DM, Griffiths GL, Wahren B, Hinkula J: Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS (2006) 20(15):1911-1915. • A study targeting viral envelope proteins on HIV-infected cells with antibodies armed with doxorubicin.
13. Hinkula J, Rollman E, Lundholm P, Benthin R, Okuda K, Wahren B: Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo. Cells Tissues Organs (2004) 177(3):169-184.
14. Berger EA, Moss B, Pastan I: Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc Natl Acad Sci USA (1998) 95(20):11511-11513.
15. Milenic DE, Brady ED, Brechbiel MW: Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov (2004) 3(6):488-499. •• A detailed overview of the current status of cancer RIT.
16. Dadachova E, Casadevall A: Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Expert Opin Drug Deliv (2005) 2(6):1075-1084. •• A detailed overview of the current status of RIT of infectious diseases.
17. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H: Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med (2006) 3(11):e427. •• A proof-of-principle study that established the utility of RIT against an experimental HIV-1 infection.
18. Dadachova E, Nakouzi A, Bryan R, Casadevall A: Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA (2003) 100(19):10942-10947. •• A proof-of-principle study showing the applicability of the RIT approach to the treatment of infectious diseases when microbes are targeted directly.
19. Spitzer ED, Spitzer SG, Freundlich LF, Casadevall A: Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 341(8845):595-596.
20. Currie BP, Casadevall A: Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 19(6):1029-1033.
21. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, Cloud GA, James R, Filler S, Dismukes WE: Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 49(3):952-958.
22. Dadachova E, Howell RW, Bryan RA, Frenkel A, Nosanchuk JD, Casadevall A: Susceptibility of the human pathogens fungi Cryptococcus neoformans and Histoplasma capsulatum to γ-radiation versus radioimmunotherapy with α- and β-emitting radioisotopes. J Nucl Med (2004) 45(2):313-320.
23. Retallack DM, Woods JP: Molecular epidemiology, pathogenesis, and genetics of the dimorphic fungus Histoplasma capsulatum. Microbes Infect (1999) 1(10):817-825.
24. Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS Jr, Casadevall A: Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest (2003) 112(8):1164-1175.
25. Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, Casadevall A, Pirofski L: Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother (2004) 48(5):1624-1629.
26. Parren PW, Moore JP, Burton DR, Sattentau QJ: The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. AIDS (1999) 13(Suppl A):S137-S162.
27. Casadevall A, Goldstein H, Dadachova E: Targeting host cells harbouring viruses with radiolabeled antibodies. Expert Opin Biol Ther (2007) 7(5):595-597.
28. Dadachova E, Wang X-G, Casadevall A: Targeting the virus with radioimmunotherapy in virus-associated cancers. Cancer Biother Radiopharm (2007) 22(3):303-308. •• A paper discussing the idea of treating virus-associated cancers with RIT directed to viral proteins expressed on cancer cells.
29. Wang X-G, Revskaya E, Bryan RA, Strickler HD, Burk RD, Casadevall A, Dadachova E: Treating cancer as an infectious disease - viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLOS One (2007) 2(10):e114. •• A proof-of-principle study demonstrating the feasibility of treating experimental virus-associated cancers with RIT directed to viral antigens expressed on cancer cells